Clearside Biomedical (CLSD)
(Real Time Quote from BATS)
$1.20 USD
-0.11 (-8.40%)
Updated Sep 23, 2024 02:48 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Clearside Biomedical, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 29 | 48 | 30 | 17 | 23 |
Receivables | 0 | 0 | 10 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 2 | 1 | 3 |
Total Current Assets | 30 | 49 | 42 | 18 | 25 |
Net Property & Equipment | 3 | 1 | 0 | 0 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 34 | 51 | 43 | 19 | 27 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 1 | 1 | 2 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 1 | 1 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 4 | 3 | 2 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 5 | 5 |
Total Current Liabilities | 7 | 6 | 5 | 10 | 11 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 4 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 42 | 34 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 50 | 41 | 5 | 11 | 16 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 305 | 299 | 293 | 265 | 249 |
Retained Earnings | -321 | -288 | -255 | -256 | -238 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -16 | 11 | 38 | 9 | 11 |
Total Liabilities & Shareholder's Equity | 34 | 51 | 43 | 19 | 27 |
Total Common Equity | -16 | 11 | 38 | 9 | 11 |
Shares Outstanding | 62.40 | 60.10 | 59.60 | 48.30 | 44.40 |
Book Value Per Share | -0.25 | 0.18 | 0.64 | 0.18 | 0.25 |
Fiscal Year End for Clearside Biomedical, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 29 | 35 | 29 | 29 | 35 |
Receivables | 0 | 0 | 0 | 1 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 1 | 1 | 1 | 1 |
Total Current Assets | 30 | 36 | 30 | 31 | 36 |
Net Property & Equipment | 3 | 3 | 3 | 3 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 34 | 40 | 34 | 34 | 39 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 1 | 2 | 2 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 4 | 4 | 4 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 6 | 6 | 7 | 6 | 5 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 56 | 42 | 41 | 38 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 62 | 62 | 50 | 47 | 44 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 312 | 311 | 305 | 303 | 302 |
Retained Earnings | -340 | -333 | -321 | -316 | -307 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -28 | -22 | -16 | -13 | -5 |
Total Liabilities & Shareholder's Equity | 34 | 40 | 34 | 34 | 39 |
Total Common Equity | -28 | -22 | -16 | -13 | -5 |
Shares Outstanding | 74.70 | 74.70 | 62.40 | 62.00 | 61.60 |
Book Value Per Share | -0.38 | -0.29 | -0.25 | -0.21 | -0.08 |